Shares of Nuformix plc (LON:NFX – Get Free Report) were down 6.5% during trading on Wednesday . The stock traded as low as GBX 0.16 and last traded at GBX 0.16. Approximately 3,252,227 shares traded hands during trading, a decline of 90% from the average session volume of 31,894,922 shares. The stock had previously closed at GBX 0.17.
Nuformix Stock Performance
The business’s fifty day moving average price is GBX 0.18 and its two-hundred day moving average price is GBX 0.21. The firm has a market capitalization of £4.15 million, a P/E ratio of -5.43 and a beta of 1.54.
Nuformix (LON:NFX – Get Free Report) last posted its quarterly earnings data on Thursday, May 28th. The company reported GBX (0.02) EPS for the quarter.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
See Also
- Five stocks we like better than Nuformix
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
- Boxabl Disrupts Housing With A Tiny Float IPO
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
